Data from Innovive Pharmaceuticals' Oncology Drug Programs to be Presented at the American Society of Hematology 49th Annual Meeting
-- Abstract # 469: "A Phase I Study of INNO-406 in Patients with Advanced Philadelphia (Ph+) Chromosome-Positive Leukemias Who Are Resistant or Intolerant to Imatinib and Second Generation Tyrosine Kinase Inhibitors." Oral Session on Chronic Myeloid Leukemia: Therapy of the CML Advanced Phases: Dec. 10 at 1:30 pm ET; Room: Thomas B. Murphy Ballroom 4
-- Abstract # 808: "ABT-737 Is a Useful Component of Combinatory Chemotherapies for Chronic Myelogenous Leukemias with Diverse Drug Resistance Mechanisms." Oral Session on Molecular Pharmacology: Drug Resistance: Dec. 11 at 7:30 am ET; Rooms: B216-B217
-- Abstract # 1598: "Anti-Tumor Effect of INNO-406, a Novel Bcr-Abl Inhibitor in Combination with Cyclosporin A Against the Murine Central Nervous System and Systemic Leukemia Model." Poster Presentation: Dec. 8 from 5:30 pm - 7:30 pm ET; Room: Hall B4, Board #752-I
-- Abstract # 2952: "Comparison of Imatinib, Dasatinib, Nilotinib and INNO-406 in Imatinib-Resistant Cell Lines." Poster Presentation: Dec. 10 from 5:00 pm - 7:00 pm ET; Room: Hall B4, Board #171-III
-- Abstract # 2931: "Glyoxalase-I Is a Potential Therapeutic Target for Chronic Myelogenous Leukemia Cells That Have Acquired Drug Resistance through Adaptation to Hypoxia." Poster Presentation: Dec. 10 from 5:00 pm - 7:00 pm ET; Room: Hall B4, Board #150-III
-- Abstract # 2951: "The Bcr-Abl Kinase Inhibitor INNO-406 Induces Autophagy and Different Modes of Cell Death Execution in Bcr-Abl-Positive Leukemias." Poster Presentation: Dec. 10 from 5:00 pm - 7:00 pm ET; Room: Hall B4, Board #170-III
-- Abstract # 903: "Pilot Study of a Wilms Tumor Protein (WT1) Heteroclitic Peptide Vaccine in Patients with Myeloid and Thoracic Neoplasms." Poster Session: Dec. 8 from 5:30 pm - 7:30 pm ET; Room: Hall B4, Board #57-I
INNO-406 (formerly known as NS-187) is a potent, oral, rationally designed, dual Bcr-Abl and Lyn-kinase inhibitor currently being investigated in a Phase I clinical study. According to a study published in the journal Blood (Dec. 1, 2005), INNO-406 is 25- to 55-times more potent than imatinib in vitro and is at least 10-times as effective as imatinib mesylate in suppressing the growth of Bcr-Abl bearing tumors. INNO-406 has demonstrated activity in 18 of 19 imatinib-resistant cell lines. In addition to its Bcr-Abl inhibitory properties, INNO-406 inhibits Lyn kinase. Upregulation of Lyn kinase activity is a well recognized cause of imatinib resistance. Lyn kinase activation has also been documented in a variety of solid tumors, including prostate cancer.
INNO-305, also known as WT1 heteroclitic peptide immunotherapy, is in a Phase I clinical trial for the treatment of patients with acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) as well as patients with non-small cell lung cancer (NSCLC) and mesothelioma. INNO-305 is unique among WT1 peptide cancer immunotherapeutics because of its ability to stimulate both CD8 and CD4 T-cells. It is believed that stimulating both types of T-cells may result in a more robust and ubiquitous immune response.
About INNOVIVE Pharmaceuticals
INNOVIVE Pharmaceuticals, Inc. acquires, develops and commercializes novel therapeutics addressing significant unmet medical needs in the fields of oncology and hematology. The company has four drug programs in clinical development: INNO-406, Tamibarotene, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, acute promyelocytic leukemia, small cell lung cancer, and acute myelogenous leukemia, respectively. For additional information visit www.innovivepharma.com.
This material contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These include statements concerning plans, objectives, goals, strategies, future events or performance and all other statements which are other than statements of historical fact, including without limitation, statements containing words such as "believes," "anticipates," "expects," "estimates," "projects," "will," "may," "might" and words of a similar nature. Such statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Among other things, there can be no assurances that any of INNOVIVE's development efforts relating to its product candidates will be successful. Other risks that may affect forward-looking information contained in this press release include the risk that the results of clinical trials may not support INNOVIVE's claims, the possibility of being unable to obtain regulatory approval of INNOVIVE's product candidates, INNOVIVE's reliance on third party researchers to develop its product candidates and its lack of experience in developing pharmaceutical products. These and other risks are discussed in INNOVIVE'S periodic reports filed with the SEC. The forward-looking statements contained herein represent the judgment of INNOVIVE as of the date this material was drafted. INNOVIVE disclaims, however, any intent or obligation to update any forward-looking statements.
Steve Kelly, President and CEO, 212-716-1820
Porter Novelli Life Sciences
Media & Investor Relations
Rachel Lipsitz, 619-849-5378
Posted: December 2007